These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9273229)

  • 1. [The influence of recombinant human erythropoietin on platelet phospholipid fatty acid composition in patients on long term hemodialysis].
    Krawczyk W; Dmoszyńska A; Ledwozyw A
    Pol Merkur Lekarski; 1996 Dec; 1(6):394-7. PubMed ID: 9273229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of human recombinant erythropoietin (rhuEPO) on platelet phospholipids in chronically hemodialysed].
    Krawczyk W; Dmoszyńska A; Ledwozyw A; Soroka-Wojtaszko M
    Acta Haematol Pol; 1993; 24(4):327-31. PubMed ID: 8303978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human erythropoietin improves the blood platelet phospholipid composition in chronically hemodialyzed patients.
    Krawczyk W; Dmoszyńska A; Marczewski K; Ledwozyw A
    Exp Nephrol; 1995; 3(4):265-6. PubMed ID: 8590040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
    de Fijter CW; Popp-Snijders C; Oe LP; Tran DD; van der Meulen J; Donker AJ
    Haematologica; 1995; 80(4):332-4. PubMed ID: 7590502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of long-term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patients.
    Sabovic M; Zupan IP; Salobir B; Zupan I; Cernelc P; Lavre J; Vujkovac B
    Thromb Haemost; 2005 Dec; 94(6):1245-50. PubMed ID: 16411401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma.
    De Castro J; Hernández-Hernández A; Rodríguez MC; Sardina JL; Llanillo M; Sánchez-Yagüe J
    Platelets; 2007 Feb; 18(1):43-51. PubMed ID: 17365853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
    Reuter SE; Faull RJ; Ranieri E; Evans AM
    Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the individual phospholipids and their fatty acids in serum and high-density lipoprotein of the renal patient on long-term maintenance hemodialysis.
    Chapkin RS; Haberstroh B; Liu T; Holub BJ
    J Lab Clin Med; 1983 May; 101(5):726-35. PubMed ID: 6833842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravenous omega-3 fatty acid infusion and hemodialysis on fatty acid composition of free fatty acids and phospholipids in patients with end-stage renal disease.
    Madsen T; Christensen JH; Toft E; Aardestrup I; Lundbye-Christensen S; Schmidt EB
    JPEN J Parenter Enteral Nutr; 2011 Jan; 35(1):97-106. PubMed ID: 21224436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment.
    Stasko J; Galajda P; Ivanková J; Hollý P; Rozborilová E; Kubisz P
    Clin Appl Thromb Hemost; 2007 Oct; 13(4):410-5. PubMed ID: 17911193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
    Aggarwal HK; Nand N; Singh S; Singh M; Hemant ; Kaushik G
    J Assoc Physicians India; 2003 Feb; 51():170-4. PubMed ID: 12725261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
    Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
    Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study.
    Hsu PY; Lin CL; Yu CC; Chien CC; Hsiau TG; Sun TH; Huang LM; Yang CW
    J Nephrol; 2004; 17(5):693-700. PubMed ID: 15593037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Transferrin microheterogeneity in patients treated by maintenance haemodialysis].
    Formanowicz D; Pietrzak I; Wiktorowicz K
    Przegl Lek; 2007; 64(7-8):483-8. PubMed ID: 18409349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin.
    Tuzcu A; Bahceci M; Yilmaz E; Bahceci S; Tuzcu S
    Horm Metab Res; 2004 Oct; 36(10):716-20. PubMed ID: 15523598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influence of hemodialysis on expression of glycoprotein lb platelets reactivity in patients with the end stage renal failure].
    Brzósko S; Hryszko T; Zak J; Wysocka J; Małyszko J; Myśliwiec M
    Przegl Lek; 2002; 59(10):823-5. PubMed ID: 12632921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
    Papavasiliou EC; Gouva C; Siamopoulos KC; Tselepis AD
    Nephrol Dial Transplant; 2006 May; 21(5):1270-7. PubMed ID: 16421163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.